Fate Therapeutics, Inc.

FATE · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$32-$34-$38-$52
Dep. & Amort.$3$3$3$5
Deferred Tax$0$0$0$0
Stock-Based Comp.$5$7$7$9
Change in WC$1$0-$5-$2
Other Non-Cash-$1-$1-$2$12
Operating Cash Flow-$24-$25-$34-$28
Investing Activities
PP&E Inv.-$2-$1-$1-$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$58-$51-$49-$38
Inv. Sales/Matur.$81$72$92$61
Other Inv. Act.$0$0$0$0
Investing Cash Flow$21$20$43$23
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$0$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$2$1$0$3
Financing Cash Flow$2$1$0$3
Forex Effect$0$0$0$0
Net Chg. in Cash-$1-$4$9-$2
Supplemental Information
Beg. Cash$51$55$46$48
End Cash$51$51$55$46
Free Cash Flow-$27-$26-$35-$28
Fate Therapeutics, Inc. (FATE) Financial Statements & Key Stats | AlphaPilot